Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 3/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.48 |
| ▸ | GAA | P10253 | 4/20 | 0.43 |
| ▸ | DRD2 | P14416 | 7/20 | 0.43 |
| ▸ | HTR1A | P08908 | 2/20 | 0.42 |
| ▸ | DRD4 | P21917 | 2/20 | 0.42 |
| ▸ | HTR2A | P28223 | 2/20 | 0.42 |
| ▸ | HTR2C | P28335 | 2/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.42 |
| ▸ | HTR7 | P34969 | 2/20 | 0.42 |
| ▸ | DRD3 | P35462 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.40 |
| ▸ | MLNR | O43193 | 1/20 | 0.40 |
| ▸ | HTR3B | O95264 | 1/20 | 0.40 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.40 |
| ▸ | ESR1 | P03372 | 1/20 | 0.40 |
| ▸ | PGR | P06401 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2016808 | 0.95 | MAOB (0.53) | MAOBKCNH2GAADRD2HTR1A | |
| SCHEMBL2017160 | 0.91 | KCNH2 (0.58) | MAOBKCNH2GAADRD2HTR1A | |
| SCHEMBL23097612 | 0.88 | MAOB (0.57) | MAOBKCNH2GAADRD2HTR1A | |
| SCHEMBL2019793 | 0.87 | MAOB (0.48) | MAOBKCNH2GAADRD2HTR1A | |
| SCHEMBL2021594 | 0.87 | KCNH2 (0.49) | MAOBKCNH2GAADRD2HTR1A | |
| SCHEMBL2019782 | 0.86 | KCNH2 (0.59) | MAOBKCNH2GAADRD2HTR1A | |
| SCHEMBL2022536 | 0.82 | MAOB (0.49) | MAOBKCNH2GAADRD2HTR1A | |
| SCHEMBL2017573 | 0.79 | MAOB (0.54) | MAOBKCNH2GAASMN1; SMN2MAPT | |
| SCHEMBL23097686 | 0.79 | DRD2 (0.64) | MAOBKCNH2GAADRD2HTR1A | |
| SCHEMBL23097620 | 0.77 | KCNH2 (0.69) | KCNH2GAADRD2HTR1ADRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2170334-B1 | NMDA RECEPTOR ANTAGONISTS FOR NEUROPROTECTION | UNIV EMORY (US) | 2021-03-17 | — | — | EP | disclosed |
| EP-2170334-B1 | NMDA RECEPTOR ANTAGONISTS FOR NEUROPROTECTION | UNIV EMORY (US) | 2021-03-17 | — | — | EP | disclosed |
| US-9079852-B2 | NMDA receptor antagonists for neuroprotection | EMORY UNIVERSITY (US) | 2015-07-14 | — | — | US | disclosed |
| US-9079852-B2 | NMDA receptor antagonists for neuroprotection | EMORY UNIVERSITY (US) | 2015-07-14 | — | — | US | disclosed |
| US-20140031363-A1 | NMDA Receptor Antagonists for Neuroprotection | LIOTTA DENNIS C (US) | 2014-01-30 | — | — | US | disclosed |
| US-20140031363-A1 | NMDA Receptor Antagonists for Neuroprotection | LIOTTA DENNIS C (US) | 2014-01-30 | — | — | US | disclosed |
| US-8420680-B2 | NMDA receptor antagonists for neuroprotection | EMORY UNIVERSITY (US) | 2013-04-16 | — | — | US | disclosed |
| US-8420680-B2 | NMDA receptor antagonists for neuroprotection | EMORY UNIVERSITY (US) | 2013-04-16 | — | — | US | disclosed |
| US-8420680-B2 | NMDA receptor antagonists for neuroprotection | EMORY UNIVERSITY (US) | 2013-04-16 | — | — | US | disclosed |
| US-20110160223-A1 | NMDA Receptor Antagonists for the Treatment of Neuropsychiatric Disorders | EMORY UNIVERSITY | 2011-06-30 | — | — | US | disclosed |
| US-20110160223-A1 | NMDA Receptor Antagonists for the Treatment of Neuropsychiatric Disorders | EMORY UNIVERSITY | 2011-06-30 | — | — | US | disclosed |
| WO-2009137843-A2 | NMDA RECEPTOR ANTAGONISTS FOR THE TREATMENT OF NEUROPSYCHIATRIC DISORDERS | EMORY UNIVERSITY (US) | 2009-11-12 | — | — | WO | disclosed |
| US-20090253710-A1 | NMDA Receptor Antagonists for Neuroprotection | EMORY UNIVERSITY | 2009-10-08 | — | — | US | disclosed |
| US-20090253710-A1 | NMDA Receptor Antagonists for Neuroprotection | EMORY UNIVERSITY | 2009-10-08 | — | — | US | disclosed |
| US-20090253710-A1 | NMDA Receptor Antagonists for Neuroprotection | EMORY UNIVERSITY | 2009-10-08 | — | — | US | disclosed |
| WO-2009006437-A1 | NMDA RECEPTOR ANTAGONISTS FOR NEUROPROTECTION | EMORY UNIVERSITY (US) | 2009-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253710-A1 | NMDA Receptor Antagonists for Neuroprotection | GRIN1, GRIN2C, GRIK1 | MAOB 3646/4885KCNH2 137/4885GAA 4217/4885 |
| US-20110160223-A1 | NMDA Receptor Antagonists for the Treatment of Neuropsychiatric Disorders | GRIN2A, GRIN2B, GRIN1 | MAOB 306/4885KCNH2 469/4885GAA 1696/4885 |
| US-20140031363-A1 | NMDA Receptor Antagonists for Neuroprotection | GRIN1, GRIN2C, GRIK1 | MAOB 3615/4885KCNH2 135/4885GAA 4301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.